Your browser doesn't support javascript.
loading
Clinical features and oncological outcomes of bladder cancer microsatellite instability.
Nagakawa, Shohei; Shiota, Masaki; Takamatsu, Dai; Tsukahara, Shigehiro; Mastumoto, Takashi; Blas, Leandro; Inokuchi, Junichi; Oda, Yoshihiro; Eto, Masatoshi.
Affiliation
  • Nagakawa S; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Shiota M; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Takamatsu D; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Tsukahara S; Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Mastumoto T; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Blas L; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Inokuchi J; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Oda Y; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Eto M; Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Int J Urol ; 31(4): 438-445, 2024 Apr.
Article in En | MEDLINE | ID: mdl-38193376
ABSTRACT

OBJECTIVES:

Excellent anticancer effect for solid tumors with microsatellite instability (MSI)-high by anti-PD-1 antibody has been reported. In this study, we investigated the clinical impact of MSI status in bladder cancer.

METHODS:

This study included 205 Japanese patients who underwent transurethral resection for bladder cancer between 2005 and 2021. The prevalence rates of microsatellite stable (MSS), MSI-low (MSI-L), and MSI-high (MSI-H) were determined using molecular testing. We examined the association of MSI status (MSS versus MSI-L/H) with clinicopathological characteristics and oncological outcomes.

RESULTS:

MSI-L/H tumors were associated with higher T-category in non-muscle invasive bladder cancer (NMIBC). Additionally, MSI-L/H tumors were associated with a higher risk of intravesical recurrence in NMIBC patients treated with intravesical bacillus Calmette-Guérin (BCG) but not with non-BCG therapy.

CONCLUSIONS:

This study suggested that the MSI status might serve as a predictive marker for intravesical recurrence after BCG intravesical therapy in NMIBC and highlighted an unmet need for an alternative treatment in patients with MSI-L/H tumors.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Non-Muscle Invasive Bladder Neoplasms Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Int J Urol Journal subject: UROLOGIA Year: 2024 Document type: Article Affiliation country: Japan

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Non-Muscle Invasive Bladder Neoplasms Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Int J Urol Journal subject: UROLOGIA Year: 2024 Document type: Article Affiliation country: Japan